Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Bio-Rad Laboratories, Inc. before investing.

In this article, we go over a few key elements for understanding Bio-Rad Laboratories, Inc.’s stock price such as:

• Bio-Rad Laboratories, Inc.’s current stock price and volume
• Why Bio-Rad Laboratories, Inc.’s stock price changed recently
• Upgrades and downgrades for BIO from analysts
• BIO’s stock price momentum as measured by its relative strength

About Bio-Rad Laboratories, Inc. (BIO)

Before we jump into Bio-Rad Laboratories, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Bio-Rad Laboratories, Inc. develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally. It operates through two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantify biological materials, including cells, proteins, and nucleic acids used in research and biopharmaceutical laboratory environments, as well as for biopharmaceutical manufacturing, quality control process, food safety, and science education applications. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology companies, food producers, and testing laboratories. Its Clinical Diagnostics segment designs, manufactures, markets, and supports diagnostic test systems, informatics systems, test kits, and specialized quality controls for clinical, hospital, diagnostic reference, and transfusion and physician office laboratories, as well as software. The company offers its products through its direct commercial organization, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.

Want to learn more about Bio-Rad Laboratories, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Bio-Rad Laboratories, Inc..

Bio-Rad Laboratories, Inc.’s Stock Price as of Market Close

As of July 31, 2026, 4:00 PM, CST, Bio-Rad Laboratories, Inc.’s stock price was $325.480.

Bio-Rad Laboratories, Inc. is down 0.38% from its previous closing price of $326.720.

During the last market session, Bio-Rad Laboratories, Inc.’s stock traded between $318.810 and $329.500. Currently, there are approximately 26.96 million shares outstanding for Bio-Rad Laboratories, Inc..

Bio-Rad Laboratories, Inc.’s price-earnings (P/E) ratio is currently at 52.2, which is high compared to the Life Sciences Tools & Services industry median of 43.7. The price-earnings ratio gauges market expectation of future performance by relating a stock’s current share price to its earnings per share.

Bio-Rad Laboratories, Inc. Stock Price History

Bio-Rad Laboratories, Inc.’s (BIO) price is currently up 10.85% so far this month.

During the month of July, Bio-Rad Laboratories, Inc.’s stock price has reached a high of $337.970 and a low of $281.790.

Over the last year, Bio-Rad Laboratories, Inc. has hit prices as high as $343.120 and as low as $236.730. Year to date, Bio-Rad Laboratories, Inc.’s stock is up 7.42%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Bio-Rad Laboratories, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of July 31, 2026, there were 0 analysts who downgraded Bio-Rad Laboratories, Inc.’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate Bio-Rad Laboratories, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Bio-Rad Laboratories, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Bio-Rad Laboratories, Inc.’s current valuation based on AAII’s Value Grade is a D, which means it is considered to be Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Bio-Rad Laboratories, Inc. (BIO) by visiting AAII Stock Evaluator.

Relative Price Strength of Bio-Rad Laboratories, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of July 31, 2026, Bio-Rad Laboratories, Inc. has a weighted four-quarter relative price strength of 8.29%, which translates to a Momentum Score of 79 and is considered to be Strong.

Want to learn more about how Bio-Rad Laboratories, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Bio-Rad Laboratories, Inc. Stock Price: Bottom Line

As of July 31, 2026, Bio-Rad Laboratories, Inc.’s stock price is $325.480, which is down 0.38% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Bio-Rad Laboratories, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.